The biology of bronchial premalignancy

Seminars in Respiratory and Critical Care Medicine

Volumn 17, Issue 4, 1996, Pages 309-322

  Franklin, Wilbur A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

BRONCHUS CANCER; CARCINOGENESIS; CHROMOSOME 3P; CHROMOSOME 9P; HUMAN; LUNG CANCER; PRECANCER; PRIORITY JOURNAL; REVIEW;

EID: 0029954755     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1009903     Document Type: Review

References (148)

1. Haaland M. Spontaneous tumours in mice. Sci Rep Invest ICRF 1911;4:1-113
2. Rous P, Beard JW. The progression to carcinoma of virus induced papillomas (Shope). J Exp Med 1935;62:523-48
3. Berenblum I, Shubik P. A new quantitative approach to the study of chemical carcinogenesis in the mouse's skin. Br J Cancer 1947;1:383-91
4. Foulds L. Neoplastic development. In: Foulds L, ed. Neoplastic Development. Academic, London, 1969;41-89
5. Doll R. An epidemiological perspective of the biology of cancer. Cancer Res 1978;38:3573-83
6. Doll R, Hill AB. Mortality in relation to smoking: ten years' observations of British doctors. Br Med J 1964;1:1399-1410
7. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks in the United States today. J Natl Cancer Inst 1981;66:1191-1308
8. Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma. JAMA 1950;143: 329-36
9. Wynder EL. Etiology of lung cancer-reflections on two decades of research. Cancer 1972;30:1332-9
10. Hammond EC Smoking in relation to the death rates of one million men and women. Monogr Natl Cancer Inst 1966; 19:127-204
11. Nettesheim P, Marchok A. Neoplastic development in airway epithelium. Adv Cancer Res 1983;39:1-70
12. Frost JK, Erozan YS, Gupta PK, Carter D. Cytopathology. In: Atlas of Early Lung Cancer. Igaku-Shoin, Tokvo, 1983; 39-76
13. Saccomanno G. Diagnostic Pulmonary Cytology American Society of Clinical Pathologists, Chicago, 1978;33-46
14. Early lung cancer detection: summary and conclusions. Am Rev Respir Dis 1984;130:565-70
15. Kennedy TC, Proudfoot SP, Franklin WA, et al. Cytopathologic evlaluation of sputum in patients with airflow obstruction and significant smoking histories. Cancer Res 1996;(In Press)
16. Saccomanno G. The contribution of uranium miners to lung cancer histogenesis. Recent Results Cancer Res 1982;82: 43-52
17. Auerbach O, Saccomanno G, Kuschner M, et al. Histologic findings in the tracheobronchial tree of uranium miners and non-miners with lung cancer. Cancer 1978;42:483-9
18. Saccomanno G, Archer VE, Saunders RP. et al. Early indices of cancer risk among uranium miners with reference to modifying factors. Ann NY Acad Sci 1976;271:377-83
19. Saccomanno G, Archer VE. Auerbach O, et al. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 1974;33:256-70
20. Saccomanno G, Archer VE, Auerbach O, et al. Histologic types of lung cancer among uranium miners. Cancer 1971;27:515-23
21. Saccomanno G, Saunders RP, Archer VE, et al. Cancer of the lung: the cytology of sputum prior to the development of carcinoma. Acta Cytol 1965;9:413-23
22. Woolner LB, Fontana RS. Cortese DA, et al. Roentgenographically occult lung cancer: pathologic findings and frequency of multicentricity during a 10-year period. Mayo Clin Proc 1984;59:453-66.
23. Martini N, Melamed MR. Occult carcinomas of the lung. Ann Thorac Surg 1980;30:215-23
24. Mason MK, Jordan JW. Outcome of carcinoma in situ and early invasive carcinoma of the bronchus. Thorax 1982; 7:453-6
25. Sanderson DR, Fontana RS. Early lung cancer detection and localization. Ann Otol Rhinol Laryngol 1975;84:583-8
26. Sato M, Saito Y, Nagamoto N, et al. Diagnostic value of differential brushing of all branches of the bronchi in patients with sputum positive or suspected positive for lung cancer. Acta Cytol 1993;37:879-83
27. Auerbach O, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking, 1955-1960 vs. 1970-1977. N Engl J Med 1979;300:381-5
28. Schluter C, Duchrow M, Wohlenberg C, et al. The cell proliferation-associated antigen of antibody Ki-67; a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993;123:513-22
29. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63
30. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133: 1710-5
31. Boers JE, ten Velde GP, Thunnissen FB. P53 in squamous metaplasia: A marker for risk of respiratory tract carcinoma Am J Respir Crit Care Med 1996;153:411-6
32. Demoly P, Simony-Lafontaine J, Chanez P, et al. Cell proliferation in the bronchial mucosa of asthmatics and chronic bronchitics. Am J Resp Crit Care Med 1994;150-214-7
33. Doria MI, Jr, Montag AG, Franklin WA. Immunophenotype of small cell lung carcinoma. Expression of NKH-1 and transferrin receptor and absence of most myeloid antigens. Cancer 1988;62:1939-45
34. Kayser K, Ernst M. Bubenzer J. Expression of transferrin- and interleukin-2-receptors, and HLA-DR in human lung carcinoma. Exp Pathol 1991;41:37-43
35. Weinberg RA. Tumor suppressor genes. [Review]. Science 1991;254:1138-46
36. Hinds PW, Finlay CA, Quartin RS, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Diff 1990;1-571-80
37. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. [Review]. Nature 1991;351:453-6
38. Iggo R, Gatter K, Bartek J, et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-9
39. Carbone DP, Mitsudomt T, Chiba I, et al. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 1994;106(Suppl):377S-381S
40. Nuorva K. Soini Y, Kamel D, et al. Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am J Pathol 1993;142:725-32
41. Bennett WP, Colby TV, Travis WD. et al. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 1993;53:4817-22
42. Sundaresan V, Ganly P. Hasleton P, et al. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene 1992;7:1989-97
43. Rusch V, Klimstra D. Linkov I, Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. Cancer Res 1995;55:1365-72
44. Rachwal WJ, Bongiorno PF, Orringer MB. et al. Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Br J Cancer 1995;72:56-64
45. Sorscher SM, Russack V, Graziano S, et al. Immunohistochemical evaluation of E-cadherin and epidermal growth factor receptor in non-small cell lung cancer. Mod Pathol 1995;8:450-5
46. Volm M, van Kaick G, Mattern J. Analysis of c-fos, c-jun, c-erbB1, c-erbB2 and c-myc in primary lung carcinomas and their lymph node metastases. Clin Exp Metastasis 1994;12:329-34
47. Bolufer P, Lluch A, Molina R, et al. Epidermal growth factor in human breast cancer, endometrial carcinoma and lung cancer. Its relationship to epidermal growth factor receptor, estradiol receptor and tumor TNM. Clinica Chimica Acta 1993;215:51-61
48. Gorgoulis V, Giatromanolaki A, Karameris A, et al. Epidermal growth factor receptor expression in squamous cell lung carcinomas: an immunohistochemical and gene analysis in formalin-fixed, paraffin-embedded material. Virchows Arch A Pathol Anat Histopathol 1993;423:295-302
49. Liu C, Tsao MS. In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas. Am J Pathol 1993;142:1155-62
50. Pavelic K, Banjac Z, Pavelic J, Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993;13:1133-7
51. Gorgoulis V, Aninos D, Mikou P, et al. Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas. Anticancer Res 1992;12:1183-7
52. Dittadi R, Gion M, Pagan V, et al. Epidermal growth factor receptor in lung malignancies. Comparison between cancer and normal tissue. Br J Cancer 1991;64:741-4
53. Dazzi H, Hasleton PS, Thatcher N, et al. Comparison of epidermal growth factor receptor expression in lung cancer by immunohistochemical staining of both frozen and formalin fixed specimens Anal Cell Pathol 1991;3:69-75
54. Sozzi G, Miozzo M, Tagliabue E, et al. Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients. Cancer Res 1991;51:400-4
55. Tungekar MF, Turley H, Dunnill MS, et al. Interleukin 4 receptor expression on human lung tumors and normal lung. Cancer Res 1991;51-261-4
56. Tateishi M, Ishida T, Mitsudomi T, et al. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 1990;50:7077-8
57. Dazzi H, Hasleton PS, Thatcher N. et al. Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGFR with histology, tumour size, node status and survival. Br J Cancer 1989;59:746-9
58. Kaseda S, Ueda M, Ozawa S, et al. Expression of epidermal growth factor receptors in four histologic cell types of lung cancer. J Surg Oncol 1989;42:16-20
59. Ozawa S, Ueda M, Ando N, et al. Epidermal growth factor receptors in cancer tissues of esophagus, lung, pancreas, colorectum. breast and stomach. Jpn J Cancer Res 1988;79:1201-7
60. Veale D, Ashcroft T, Marsh C, et al. Epidermal growth factor receptors in non-small cell lung cancer Br J Cancer 1987;55:515-6
61. Berger MS, Greenficld C, Waterfield MD. .Altered expression of epidermal growth factor receptors in human bladder and lung tumours. Princess Takamatsu Symp 1986;17:183-94
62. Hwang DL, Tay YC. Lin SS, Lev-Ran A. Expression of epidermal growth factor receptors in human lung tumors. Cancer 1986;58:2260-3
63. Franklin WA. Immunophenotypic changes associated with neoplastic transformation of human respiratory tract epithelium. Lung Cancer 1994;4:15-36
64. Beverley PC, Souhami RL, Bobrow L. Proceedings of the first international workshop on small cell lung cancer antigens. Lung Cancer 1988;4:15-36(Abstract)
65. Takamatsu K, Auerbach B, Gerardy-Schahn R, et al. Evaluation of the binding properties of monoclonal antibodies submitted to Third International IASLC Workshop on Lung Tumor and Differentiation Antigens to Neural Cell Adhesion Molecule. Int J Cancer 1995;8(Suppl):30-3
66. Senderovitz T, Skov BG, Hirsch FR. Neuroendocrine characteristics in malignant lung rumors: implications for diagnosis, treatment, and prognosis. Cancer Treat Res 1995;72:143-54
67. Michalides R, Kwa B, Springall D, et al. NCAM and lung cancer. Int J Cancer 1994;8(Suppl):34-7
68. Baldissarro I, Marroni P, Smilovich D, et al. Biochemical characterization and membrane expression of an antigen shared by activated and neoplastic cells of neuroectodermal origin. J Neuroimmunol 1995;57:17-26
69. Broers JL, Ramaekers FC. Differentiation markers for lungcancer sub-types. A comparative study of their expression in vivo and in vitro. [Review]. Int J Cancer 1994;8(Suppl): 134-7
70. Damstrup L, Rygaard K, Spang-Thomsen M, Poulsen HS. Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. Cancer Res 1992;52:3089-93
71. Lee WH, Shew JY, Hong FD, et al. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 1987;329:642-5
72. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986;323:643-6
73. Lee WH, Chen PL, Riley DJ. Regulatory networks of the retinoblastoma protein. Ann NY Acad Sci 1995;752:432-45
74. Horowitz JM, Park SH, Bogenmann E, et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 1990;87:2775-9
75. Otterson GA, Kratzke RA, Coxon A, et al. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 1994;9:3375-8
76. Hensel CH. Hsieh CL, Gazdar AF. et al. Altered structure and expression of the human retinoblastoma susceptibili-ty gene in small cell lung cancer. Cancer Res 1990;50: 3067-72
77. Yokota J, Akiyama T, Fung YK, et al. Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 1988;3:471-5
78. Xu HJ, Quinlan DC, Davidson AG, et al. Altered retinoblastoma protein expression and prognosis in early-stage nonsmall-cell lung carcinoma. J Natl Cancer Inst 1994;86:695-9
79. Reissmann PT, Koga H, Takahashi R, et al. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene 1993;8:1913-9
80. Maisch SA, Brown RW, Gondo M, et al. Rb expression in preinvasive and invasive squamous lesions of the bronchus: immunohistochemical evaluation of 312 endobronchial biopsies. (Abstract) Mod Pathol 1996;9:160A
81. Franklin WA, Waintrub M, Edwards D, et al. New anti-lung-cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer 1994;8(Suppl):89-95
82. MacAulay C, Lam S, Payne PW. et al. Malignancy-associated changes in bronchial epithelial cells in biopsy specimens. Anal Quant Cytol Histol 1995;17:55-61
83. Palcic B. Nuclear texture: can it be used as a surrogate endpoint biomarker? J Cell Biochem 1994;19(Suppl)40-6
84. Mitsudomi T, Steinberg SM, Nau MM, et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992;7:171-80
85. Suzuki H, Takahashi T, Kuroishi T, et al. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res 1992;52:734-6
86. Takahashi T. Suzuki H. Hida T, et al. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene 1991;6:1775-8
87. Sameshima Y, Matsuno Y, Hirohashi S, et al. Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene 1992;7:451-7
88. Miller CW, Simon K, Aslo A, et al. p53 mutations in human lung tumors. Cancer Res 1992;52:1695-8
89. D'Amico D, Carbone D, Mitsudomi T, et al. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 1992;7:339-46
90. Chiba I, Takahashi T, Nau MM, et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer-Lung Cancer Study Group. Oncogene 1990;5:1603-10
91. Kishimoto Y, Murakami Y, Shiraishi M, et al. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 1992;52:4799-4804
92. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78
93. Field JK, Zoumpourlis V, Spandidos DA, Jones AS. p53 expression and mutations in squamous cell carcinoma of the head and neck: expression correlates with the patients' use of tobacco and alcohol. Cancer Detect Prev 1994;18:197-208
94. Gosney JR, Butt SA, Gosney MA, Field JK. Exposure to cigarette smoke and expression of the protein encoded by the p53 gene in bronchial carcinoma. Ann NY Acad Sci 1993;686:243-8
95. Westra WH, Offerhaus GJ, Goodman SN, et al. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 1993;17:213-20
96. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:712-7
97. Franceschi S, Gloghini A, Maestro R, et al. Analysis of the p53 gene in relation to tobacco and alcohol in cancers of the upper aero-digestive tract. Int J Cancer 1995;60:872-6
98. Suzuki T, Shidara K, Hara F, Nakajima T. High frequency of p53 abnormality in laryngeal cancers of heavy smokers and its relation to human papillomavirus infection. Jpn J Cancer Res 1994,85:1087-93
99. Boyle JO, Hakim J, Koch W, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993;53:4477-80
100. Sozzi G, Miozzo M, Pastorino U, et al. Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res 1995;55:135-40
101. Sozzi G, Miozzo M. Donghi R, et al. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 1992;52:6079-82
102. Franklin WA, Low R, Haney J, LaRosa FG. Genetic profiles of metachronous lung carcinomas and preneoplastic lesions. (Abstract) Mod Pathol 1996;9:156
103. Rodenhuis S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992;52: 2665S-2669S
104. Rodenhuis S, van de Wetering ML, Mooi WJ. et al. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987;317:929-35
105. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 1993;366:643-54
106. Hall A. A biochemical function for Ras - at last. Science 1994;2641413-4
107. Mao L, Hruban RH, Boyle JO, et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994;54:1634-7
108. Mills NE, Fishman CL, Scholes J, et al. Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis [see comments]. J Natl Cancer Inst 1995;87:1056-60
109. Sugio K, Kishimoto Y, Virmani AK, et al. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res 1994;54:5811-5
110. Whang-Peng J, Kao-Shan CS, Lee EC, et al. Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science 1982;215:181-2
111. Harbour JW, Lai SL, Whang-Peng J, et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988;241:353-7
112. Rygaard K, Nakamura T, Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 1993; 67:37-46
113. Sachse R, Murakami Y, Shiraishi M, et al. DNA aberrations at the retinoblastoma gene locus in human squamous cell carcinomas of the lung. Oncogene 1994;9:39-47
114. Kashii T, Mizushima Y, Monno S, et al. Gene analysis of K-, Hras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method. J Cancer Res Clin Oncol 1994;120:143-8
115. Siden TS, Golembieski W. Kumlien J, et al. Physical map of small cell lung cancer deletion region on short arm of human chromosome 3 (3p13-22) based on radiation fusion hybrid analysis. Somat Cell Mol Genet 1994;20:121-32
116. Johnson BE, Sakaguchi AY, Gazdar AF, et al. Restriction fragment length polymorphism studies show consistent loss of chromosome 3p alleles in small cell lung cancer patients' tumors. J Clin Invest 1988;82:502-7
117. Naylor SL, Johnson BE, Minna JD, Sakaguchi AY Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 1987;329:451-4
118. Brauch H, Johnson B, Hovis J, et al. Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. N Engl J Med 1987;317:1109-13
119. Rabbitts P, Douglas J, Daly M, et al. Frequency and extent of allelic loss in the short arm of chromosome 3 in non-small-cell lung cancer. Genes Chromosom Cancer 1989;1: 95-105
120. Testa JR, Siegfried JM, Liu Z, et al. Cytogenetic analysis of 63 non-small cell lung carcinomas: recurrent chromosome alterations amid frequent and widespread genomic upheaval. Genes Chromosom Cancer 1994;11:178-94
121. Hibi K, Takahashi T, Yamakawa K, et al. Three distinct regions involved in 3p deletion in human lung cancer. Oncogene 1992;7.445-9
122. Hung J, Kishimoto Y, Sugio K, et al Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma [published erratum appears in JAMA 1995 Jun 28;273(24):1908]. JAMA 1995;273:558-63
123. Franklin WA, Todd S, Gemmill RM, et al. Correlative assessment of morphologic, immunophenotypic and genetic changes in bronchial epithelium of tobacco smokers. Chest 1996;109:268
124. Merlo A, Gabrielson E, Mabry M, et al. Homozygous deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in primary human small cell lung cancer. Cancer Res 1994;54:2322-6
125. Olopade OI, Buchhagen DL, Malik K, et al. Homozygous loss of the Interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res 1993; 53(Suppl):2410-5
126. Serrano M. Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 [see comments]. Nature 1993;366:704-7
127. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types [see comments]. Science 1994;264:436-40
128. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest [see comments]. Nature 1994;371:257-61
129. Xiao S, Li D, Corson JM, et al. Codeletion of n15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res 1995;55:2968-71
130. Washimi O, Nagatake M, Osada H, et al. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 1995;55:514-7
131. Clurman BE, Roberts JA. Cell cycle and cancer. J Natl Cancer Inst 1995;87:1499-1001
132. Cairns P, Mao L, Merlo A, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss [letter; comment]. Science 1994;265:415-17
133. Merlo A, Gabrielson E, Askin F, Sidransky D. Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res 1994;54:640-2
134. Coleman A, Fountain JW, Nobori T, et al. Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia. Cancer Res 1994;54:344-8
135. Neville EM, Stewart M, Myskow M, et al. Loss of heterozygosity at 9p23 defines a novel locus in non-small cell lung cancer. Oncogene 1995;11.581-5
136. Mead LJ, Gillespie MT, Irving LB, Campbell LJ. Homozygous and hemizygous deletions of 9p centromeric to the Interferon genes in lung cancer. Cancer Res 1994;54:2307-9
137. Kishimoto Y, Sugio K, Hung JY, et al. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers [see comments]. J Nad Cancer Inst 1995;87:1224-9
138. Johnson BE, Brennan JF, Ihde DC, Gazdar AF. myc family DNA amplification in tumors and tumor cell lines from patients with small-cell lung cancer. Monogr Natl Cancer Inst 1992;39-43
139. Makela TP, Saksela K, Alitalo K. Amplification and rearrangement of L-myc in human small-cell lung cancer. Mutat Res 1992;276:307-315
140. Ibson JM. Waters JJ, Twentyman PR, et al. Oncogene amplification and chromosomal abnormalities in small cell lung cancer. J Cell Biochem 1987;33:267-88
141. Johnson BE, Ihde DC, Makuch RW, et al. myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest 1987;79:1629-34
142. Nau MM, Brooks BJ, Jr, Carney DN, et al. Human small-cell lung cancers show amplification and expression of the N-myc gene. Proc Natl Acad Sci USA 1986;83:1092-6
143. Nau MM, Brooks BJ, Battey J, et al. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature 1985;318:69-73
144. Marchetti A, Buttitta F, Pellegrini S, et al. mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol 1995;4:93-7
145. Kern JA, Robinson RA, Gazdar A, et al. Mechanisms of p185HER2 expression in human non-small cell lung cancer cell lines. Am J Respir Cell Mol Biol 1992;6:359-63
146. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line [see comments]. Science 1992;258:1650-4
147. Eijdems EW, De Haas M, Coco-Martin JM, et al. Mechanisms of MRP over-expression in four human lung-cancer cell lines and analysis of the MRP amplicon. Int J Cancer 1995;60:676-84
148. Ray ME, Guan XY, Slovak ML, et al. Rapid detection, cloning and molecular cytogenetic characterisation of sequences from an MRP-encoding amplicon by chromosome microdissection. Br J Cancer 1994;70:85-90